The US FDA (Food and Drug Administration) has issued a safety communication concerning the separation of lubricious coatings from intravascular medical devices. The message aims to make healthcare providers aware of the possibility that hydrophilic and/or hydrophobic coatings may separate from medical devices and cause serious injuries to patients.
The Monarch eTNS system has been granted CE mark approval as a treatment for treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults and children age 7 and older. According to NeuroSigma, this is the first CE mark approval for a non-drug treatment of ADHD in the European Union.
The Data Safety and Monitoring Board has conducted its second pre-planned safety review of the phase 2 clinical trial of NurOwn in amyotrophic lateral sclerosis, according to a press release from BrainStorm. This randomised, double-blind, placebo-controlled phase 2 clinical trial is being conducted at three US academic medical centres.
Neuravi has announced that the Tennessee Interventional and Imaging Associates at Erlanger Medical Center in Chattanooga, USA, have treated the first patient in an international clinical trial assessing safety and effectiveness of the EmboTrap Revascularisation Device, a novel stent retriever for the treatment of acute ischaemic stroke. Data from the pivotal study, called ARISE II (Analysis of revascularization in ischemic stroke with EmboTrap), will be submitted as part of an application to US Food and Drug Administration (FDA) for approval for the device.
A meta-analysis published in the Journal of the American Medical Association (JAMA) has found that endovascular intervention compared to standard medical care can be associated with improved functional outcomes and higher rates of functional independence at 90 days.
The first patient has been enrolled in the US ROADSTER 2 post approval study at Greenville Memorial Hospital in Greenville, USA.
According to an article published by the Journal of the American Medicine Association (JAMA) Neurology, treating symptomatic intracerebral haemorrhage (sICH) after clot-busting thrombolysis for stroke was not associated with a reduced likelihood of in-hospital death or expansion of the haematoma. Shortening time to diagnosis and treatment, however, may be key to improving outcomes.
Patients with high baseline diastolic blood pressure undergoing carotid endarterectomy are at increased risk of stroke, myocardial infarction, or death within 30 days of the procedure, according to results from the International Carotid Stenting Study (ICSS). In a paper published in the European Journal of Vascular and Endovascular Surgery, the authors say that in the context of a single preoperative measurement of blood pressure, diastolic blood pressure might be a better predictor than systolic blood pressure.
James Bond´s nemesis in the most recent film likely failed neuroanatomy, said real-life neurosurgeon and scientist Dr. Michael Cusimano of St. Michael´s Hospital.
The out-of-hospital birth setting in Oregon was associated with a higher risk of perinatal death, while the in-hospital birth setting was associated with a higher risk for cesarean delivery and other obstetric interventions (e.g., induction or augmentation of labor), according a study published today in the New England Journal of Medicine by researchers at Oregon Health & Science University.
Using mice whose front paws were still partly disabled after an initial induced stroke, Johns Hopkins researchers report that inducing a second stroke nearby in their brains let them “rehab” the animals to successfully grab food pellets with those paws at pre-stroke efficiency.
New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA™, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. DURLAZA is now commercially available for physicians and their patients
Scientists at VIB and KU Leuven have identified the oxygen sensor PHD1 as a potential target for the treatment of brain infarction (ischemic stroke). Despite (minor) improvements in stroke treatment, stroke remains the fourth leading cause of death and the most common reason of severe disability. The impact of stroke is overwhelming for the patient, family and society -representing one of the largest unmet medical needs. Research led by prof. Peter Carmeliet and dr. Annelies Quaegebeur (VIB/KU Leuven) indicates that inhibition of PHD1 offers protection against stroke, via an unexpected mechanism, raising hope for future stroke treatment. The study was published in the leading medical journal Cell Metabolism.
A UT Southwestern Medical Center study to evaluate nursing protocols designed to better triage and treat stroke patients using telemedicine will be the first study using a new consortium of medical centers.
Researchers stress the need for early occlusion of subarachnoid aneurysms to prevent death from rebleeding.
Cookies Sociales
Son esos botones que permiten compartir el contenido del sitio web en sus redes sociales (Facebook, Twitter y Linkedin, previo tu consentimiento y login) a través de sistemas totalmente gestionados por dichas redes sociales, así como los recursos (pej. videos) y material que se encuentra en nuestra web, y que de igual manera se presta y gestiona completamente por un tercero.
Si no acepta estas cookies, no podrá compartir nuestro contenido a través de los botones, y en su caso, no podrás visualizar el contenido de terceros que hayamos incrustado en el sitio.
No las utilizamos